C-suite reality: how to resource your next product when it competes with your lead
This article was originally published in Scrip
A bovine extracted product, or a human recombinant one? The choice isn't that obvious, especially if neither product has human proof of concept and the bovine product is less clinically advanced. This is the real dilemma that AM-Pharma faced in 2011, as chief executive officer Erik van den Berg explains to Mike Ward. In the end, AM raised nearly €30m and was able to forge ahead with the market's preferred product. But the case illustrates that for smaller companies, strategy decides between the best available options, not between ideal ones.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.